Anti-(+)-Methamphetamine Monoclonal Antibody Antagonists Designed to Prevent the Progression of Human Diseases of Addiction
2010; Wiley; Volume: 88; Issue: 3 Linguagem: Inglês
10.1038/clpt.2010.155
ISSN1532-6535
AutoresW. Brooks Gentry, Daniela Rüedi‐Bettschen, S. Michael Owens,
Tópico(s)HIV Research and Treatment
ResumoAnti-(+)-methamphetamine monoclonal antibodies (mAbs) have the potential to reduce the devastating behavioral and societal effects of the worldwide epidemic of (+)-methamphetamine (METH) addiction and transform the treatment paradigm for diseases of addiction. These novel, protein-based medications could play a vital role in helping patients to achieve sustainable abstinence from METH abuse by serving as an in vivo, around-the-clock sentry against a patient's vulnerability to relapse.
Referência(s)